{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T05:41:48Z","timestamp":1669873308193},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s00104-022-01694-9","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T16:02:44Z","timestamp":1661011364000},"page":"1126-1132","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aktueller Stand der chirurgischen Therapie peritonealer Metastasen bei kolorektalen Karzinomen"],"prefix":"10.1007","volume":"93","author":[{"given":"Can","family":"Yurttas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus W.","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"1694_CR1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1245\/s10434-019-07935-2","volume":"27","author":"D Baratti","year":"2020","unstructured":"Baratti\u00a0D, Kusamura\u00a0S, Azmi\u00a0N et al (2020) Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C\u2011based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol 27:98\u2013106","journal-title":"Ann Surg Oncol"},{"key":"1694_CR2","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.21037\/jgo-2020-05","volume":"12","author":"P Cashin","year":"2021","unstructured":"Cashin\u00a0P, Sugarbaker\u00a0PH (2021) Hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases: lessons learned from PRODIGE 7. J\u00a0Gastrointest Oncol 12:S120\u2013S128","journal-title":"J Gastrointest Oncol"},{"key":"1694_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"Driel\u00a0WJ van, Koole\u00a0SN, Sikorska\u00a0K et\u00a0al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N\u00a0Engl J Med 378:230\u2013240","journal-title":"N Engl J Med"},{"key":"1694_CR4","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1002\/cncr.25116","volume":"116","author":"J Franko","year":"2010","unstructured":"Franko\u00a0J, Ibrahim\u00a0Z, Gusani\u00a0NJ et\u00a0al (2010) Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116:3756\u20133762","journal-title":"Cancer"},{"key":"1694_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko\u00a0J, Shi\u00a0Q, Goldman\u00a0CD et\u00a0al (2012) Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a\u00a0pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J\u00a0Clin Oncol 30:263\u2013267","journal-title":"J Clin Oncol"},{"key":"1694_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/jso.21332","volume":"100","author":"G Glockzin","year":"2009","unstructured":"Glockzin\u00a0G, Ghali\u00a0N, Lang\u00a0SA et\u00a0al (2009) Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. J\u00a0Surg Oncol 100:306\u2013310","journal-title":"J Surg Oncol"},{"issue":"15_suppl","key":"1694_CR7","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2018.36.15_suppl.3531","volume":"36","author":"D Goere","year":"2018","unstructured":"Goere\u00a0D, Glehen\u00a0O, Quenet\u00a0F et al (2018) Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-NTC01226394). J\u00a0Clin Oncol 36(15_suppl):3531","journal-title":"J Clin Oncol"},{"key":"1694_CR8","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","volume":"22","author":"D Goere","year":"2015","unstructured":"Goere\u00a0D, Souadka\u00a0A, Faron\u00a0M et\u00a0al (2015) Extent of colorectal peritoneal carcinomatosis: attempt to define a\u00a0threshold above which HIPEC does not offer survival benefit: a\u00a0comparative study. Ann Surg Oncol 22:2958\u20132964","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1694_CR9","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/cancers13102471","volume":"13","author":"P Horvath","year":"2021","unstructured":"Horvath\u00a0P, Yurttas\u00a0C, Beckert\u00a0S et al (2021) Twelve-year single center experience shows safe implementation of developed peritoneal surface malignancy treatment protocols for gastrointestinal and gynecological primary tumors. Cancers (Basel) 13(10):2471","journal-title":"Cancers (Basel)"},{"key":"1694_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet\u00a0P, Sugarbaker\u00a0PH (1996) Peritoneal-plasma barrier. Cancer Treat Res 82:53\u201363","journal-title":"Cancer Treat Res"},{"key":"1694_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","volume":"4","author":"CEL Klaver","year":"2019","unstructured":"Klaver\u00a0CEL, Wisselink\u00a0DD, Punt\u00a0CJA et al (2019) Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a\u00a0multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4:761\u2013770","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1694_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00268-014-2801-y","volume":"39","author":"AM Kuijpers","year":"2015","unstructured":"Kuijpers\u00a0AM, Aalbers\u00a0AG, Nienhuijs\u00a0SW et\u00a0al (2015) Implementation of a\u00a0standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg 39:453\u2013460","journal-title":"World J Surg"},{"key":"1694_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejso.2015.08.162","volume":"42","author":"AM Kuijpers","year":"2016","unstructured":"Kuijpers\u00a0AM, Hauptmann\u00a0M, Aalbers\u00a0AG et\u00a0al (2016) Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol 42:244\u2013250","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1694_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1245\/s10434-021-10769-6","volume":"29","author":"CR Pameijer","year":"2022","unstructured":"Pameijer\u00a0CR (2022) HIPEC Trials and the US: A Review and Call to Action Ann Surg Oncol 29(2):866\u2013872. https:\/\/doi.org\/10.1245\/s10434-021-10769-6","journal-title":"Ann Surg Oncol"},{"key":"1694_CR15","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-022-09572-7","volume":"22","author":"F Pereira","year":"2022","unstructured":"Pereira\u00a0F, Serrano\u00a0A, Manzanedo\u00a0I et al (2022) GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin\u2011C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases. BMC Cancer 22:536","journal-title":"BMC Cancer"},{"issue":"2","key":"1694_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net\u00a0F, Elias\u00a0D, Roca\u00a0L et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):256\u2013266","journal-title":"Lancet Oncol"},{"key":"1694_CR17","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ejso.2021.01.018","volume":"47","author":"DJ Repullo","year":"2021","unstructured":"Repullo\u00a0DJ, Barbois\u00a0S, Leonard\u00a0D et\u00a0al (2021) The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective analysis. Eur J Surg Oncol 47:1661\u20131667","journal-title":"Eur J Surg Oncol"},{"key":"1694_CR18","unstructured":"Robert Koch-Institut (2021) Krebs in Deutschland f\u00fcr 2017\/2018. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2021\/krebs_in_deutschland_2021.pdf?__blob=publicationFile. Zugegriffen: 27. Mai 2022"},{"key":"1694_CR19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12885-019-5545-0","volume":"19","author":"KP Rovers","year":"2019","unstructured":"Rovers\u00a0KP, Bakkers\u00a0C, Simkens\u00a0G et al (2019) Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a\u00a0multicentre, open-label, parallel-group, phase II\u2013III, randomised, superiority study (CAIRO6). BMC Cancer 19:390","journal-title":"BMC Cancer"},{"key":"1694_CR20","doi-asserted-by":"publisher","first-page":"e202701","DOI":"10.1001\/jamaoncol.2020.2701","volume":"6","author":"KP Rovers","year":"2020","unstructured":"Rovers\u00a0KP, Bakkers\u00a0C, Erning\u00a0FN van et\u00a0al (2020) Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases. JAMA Oncol 6:e202701","journal-title":"JAMA Oncol"},{"key":"1694_CR21","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1016\/S1470-2045(21)00063-2","volume":"22","author":"KP Rovers","year":"2021","unstructured":"Rovers\u00a0KP, Kok\u00a0NFM, Punt\u00a0CJA et\u00a0al (2021) Limitations of the PRODIGE 7 trial. Lancet Oncol 22:e174","journal-title":"Lancet Oncol"},{"key":"1694_CR22","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1245\/s10434-017-5821-7","volume":"24","author":"MA Schneider","year":"2017","unstructured":"Schneider\u00a0MA, Eshmuminov\u00a0D, Lehmann\u00a0K (2017) Major postoperative complications are a\u00a0risk factor for impaired survival after CRS\/HIPEC. Ann Surg Oncol 24:2224\u20132232","journal-title":"Ann Surg Oncol"},{"key":"1694_CR23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider\u00a0MA, Eden\u00a0J, Pache\u00a0B et al (2018) Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 268:845\u2013853","journal-title":"Ann Surg"},{"key":"1694_CR24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman\u00a0J, Granath\u00a0F, Holm\u00a0T et\u00a0al (2012) Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 99:699\u2013705","journal-title":"Br J Surg"},{"issue":"5","key":"1694_CR25","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/cancers14051158","volume":"14","author":"N Seyfried","year":"2022","unstructured":"Seyfried\u00a0N, Yurttas\u00a0C, Burkard\u00a0M et\u00a0al (2022) Prolonged exposure to oxaliplatin during HIPEC improves effectiveness in a preclinical micrometastasis model. Cancers (Basel) 14(5):1158","journal-title":"Cancers (Basel)"},{"key":"1694_CR26","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","volume":"22","author":"GA Simkens","year":"2015","unstructured":"Simkens\u00a0GA, Oudheusden\u00a0TR van, Luyer\u00a0MD et\u00a0al (2015) Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol 22:2656\u20132662","journal-title":"Ann Surg Oncol"},{"key":"1694_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CMAR.S119569","volume":"9","author":"GA Simkens","year":"2017","unstructured":"Simkens\u00a0GA, Rovers\u00a0KP, Nienhuijs\u00a0SW et\u00a0al (2017) Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 9:259\u2013266","journal-title":"Cancer Manag Res"},{"key":"1694_CR28","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1245\/s10434-013-3061-z","volume":"21","author":"K Turaga","year":"2014","unstructured":"Turaga\u00a0K, Levine\u00a0E, Barone\u00a0R et\u00a0al (2014) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 21:1501\u20131505","journal-title":"Ann Surg Oncol"},{"key":"1694_CR29","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink\u00a0I, Bolhaqueiro\u00a0ACF, Elias\u00a0SG et\u00a0al (2019) Organoids from colorectal peritoneal metastases as a\u00a0platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg 106:1404\u20131414","journal-title":"Br J Surg"},{"key":"1694_CR30","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal\u00a0VJ, Bruin\u00a0S, Boot\u00a0H et al (2008) 8\u2011year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426\u20132432","journal-title":"Ann Surg Oncol"},{"key":"1694_CR31","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal\u00a0VJ, Ruth\u00a0S van, Bree\u00a0E\u00a0de et\u00a0al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J\u00a0Clin Oncol 21:3737\u20133743","journal-title":"J Clin Oncol"},{"key":"1694_CR32","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","volume":"47","author":"VCJ van de Vlasakker","year":"2021","unstructured":"Vlasakker\u00a0VCJ van de, Lurvink\u00a0RJ, Cashin\u00a0PH et al (2021) The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 47:2888\u20132892","journal-title":"Eur J Surg Oncol"},{"key":"1694_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1245\/s10434-016-5712-3","volume":"24","author":"K Waite","year":"2017","unstructured":"Waite\u00a0K, Youssef\u00a0H (2017) The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol 24:705\u2013720","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1694_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/jcm7120567","volume":"7","author":"C Yurttas","year":"2018","unstructured":"Yurttas\u00a0C, Hoffmann\u00a0G, Tolios\u00a0A et\u00a0al (2018) Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J\u00a0Clin Med 7(12):567","journal-title":"J Clin Med"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01694-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-022-01694-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-022-01694-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T19:11:10Z","timestamp":1669835470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-022-01694-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1007\/s00104-022-01694-9","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"18 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Yurttas, M.W.\u00a0L\u00f6ffler, A.\u00a0K\u00f6nigsrainer und P.\u00a0Horvath geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}